- Home
- BLFS vs NTLA Comparison
BLFS vs NTLA Comparison
Compare BLFS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- NTLA
- Stock Information
- Founded
- BLFS 1987
- NTLA 2014
- Country
- BLFS United States
- NTLA United States
- Employees
- BLFS N/A
- NTLA N/A
- Industry
- BLFS Medical/Dental Instruments
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BLFS Health Care
- NTLA Health Care
- Exchange
- BLFS Nasdaq
- NTLA Nasdaq
- Market Cap
- BLFS 1.3B
- NTLA 1.2B
- IPO Year
- BLFS 1989
- NTLA 2016
- Fundamental
- Price
- BLFS $24.10
- NTLA $8.34
- Analyst Decision
- BLFS Strong Buy
- NTLA Buy
- Analyst Count
- BLFS 5
- NTLA 22
- Target Price
- BLFS $30.60
- NTLA $19.83
- AVG Volume (30 Days)
- BLFS 327.5K
- NTLA 11.8M
- Earning Date
- BLFS 11-06-2025
- NTLA 11-06-2025
- Dividend Yield
- BLFS N/A
- NTLA N/A
- EPS Growth
- BLFS N/A
- NTLA N/A
- EPS
- BLFS N/A
- NTLA N/A
- Revenue
- BLFS $100,144,000.00
- NTLA $57,528,000.00
- Revenue This Year
- BLFS $25.65
- NTLA $8.51
- Revenue Next Year
- BLFS $14.81
- NTLA N/A
- P/E Ratio
- BLFS N/A
- NTLA N/A
- Revenue Growth
- BLFS 87.53
- NTLA 33.52
- 52 Week Low
- BLFS $19.10
- NTLA $5.90
- 52 Week High
- BLFS $29.62
- NTLA $28.25
- Technical
- Relative Strength Index (RSI)
- BLFS 33.03
- NTLA 29.93
- Support Level
- BLFS $25.49
- NTLA $8.96
- Resistance Level
- BLFS $28.21
- NTLA $10.33
- Average True Range (ATR)
- BLFS 1.00
- NTLA 1.08
- MACD
- BLFS -0.44
- NTLA -0.62
- Stochastic Oscillator
- BLFS 8.19
- NTLA 2.34
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.